Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.04 and traded as high as $0.06. Mateon Therapeutics shares last traded at $0.05, with a volume of 179,981 shares traded.
Mateon Therapeutics Stock Performance
The business has a 50-day moving average price of $0.05 and a two-hundred day moving average price of $0.04.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Further Reading
- Five stocks we like better than Mateon Therapeutics
- Roth IRA Calculator: Calculate Your Potential Returns
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- Transportation Stocks Investing
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- 3 Dividend Kings To Consider
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
